Zepbound vs Wegovy: UK Weight Loss Comparison

Zepbound and Wegovy represent the two most effective licensed weight loss medications currently available, each backed by a major pharmaceutical company and extensive clinical trial data. Understanding what each product is — and how they relate to their "sister" brands — is essential.

Zepbound (tirzepatide) — Eli Lilly - Active ingredient: Tirzepatide - Class: Dual GIP/GLP-1 receptor agonist - Specifically licensed for weight management (chronic weight management in adults with obesity or overweight with at least one weight-related condition) - Same active compound as Mounjaro (which is licensed for type 2 diabetes) - Once-weekly subcutaneous injection - Dose range: 2.5mg to 15mg - FDA approved November 2023; UK/MHRA regulatory status is evolving

Wegovy (semaglutide 2.4mg) — Novo Nordisk - Active ingredient: Semaglutide - Class: GLP-1 receptor agonist - Specifically licensed for weight management - Same active compound as Ozempic (which is licensed for type 2 diabetes, at lower doses) - Once-weekly subcutaneous injection - Dose range: 0.25mg to 2.4mg - MHRA approved and available in the UK since 2022

The branding distinction is important: Zepbound and Mounjaro contain identical tirzepatide but are approved for different indications (weight management vs type 2 diabetes, respectively). Similarly, Wegovy and Ozempic contain the same semaglutide but at different doses and for different indications. In the UK, the availability and funding pathways differ depending on which brand name and indication are used.

UK availability note: As of early 2026, Zepbound's UK regulatory status is still developing. Mounjaro (tirzepatide for diabetes) is available, and some private prescribers are prescribing tirzepatide off-label for weight management pending full Zepbound availability. This guide discusses tirzepatide for weight loss under the Zepbound branding for clarity, but UK consumers should confirm current availability with their prescriber.

The fundamental difference between Zepbound and Wegovy is their mechanism of action — and this difference likely explains Zepbound's superior weight loss results.

Wegovy (semaglutide) — GLP-1 receptor agonist: Semaglutide activates the GLP-1 (glucagon-like peptide-1) receptor, producing several effects: - Appetite suppression: Reduces hunger signals from the hypothalamus, leading to decreased food intake - Gastric slowing: Delays stomach emptying, promoting feelings of fullness after smaller meals - Insulin secretion: Enhances glucose-dependent insulin release, improving blood sugar control - Cardiovascular protection: The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events

GLP-1 is a natural hormone released by the gut after eating. Semaglutide is a modified version with a much longer half-life (~7 days vs minutes for natural GLP-1), allowing once-weekly dosing.

Zepbound (tirzepatide) — dual GIP/GLP-1 receptor agonist: Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors: - All of the GLP-1 effects described above - GIP receptor activation adds complementary effects: - Enhanced insulin secretion through a different pathway - Improved fat metabolism and adipose tissue function - Potential direct effects on brain appetite centres via a distinct mechanism - May mitigate some GLP-1-related nausea (possibly explaining Zepbound's better GI tolerability)

Why dual targeting may be superior: The GLP-1 and GIP pathways are complementary rather than redundant. By activating both simultaneously, tirzepatide may achieve a more comprehensive metabolic effect than GLP-1 activation alone. Research suggests that GIP receptor activation: - Enhances the brain's response to satiety signals through pathways that differ from GLP-1 - Improves the body's ability to metabolise fat rather than simply suppressing intake - May have direct effects on adipose tissue, promoting healthier fat storage and mobilisation

This dual mechanism is the most likely explanation for tirzepatide's consistently superior weight loss results compared to semaglutide in clinical trials.

Both medications have been tested in large, well-designed clinical trials. Here is the head-to-head data:

Wegovy — STEP trial programme: - STEP 1 (non-diabetic obesity): 14.9% mean weight loss at 68 weeks - STEP 2 (type 2 diabetes): 9.6% mean weight loss at 68 weeks - STEP 3 (with intensive behavioural therapy): 16.0% mean weight loss at 68 weeks - STEP 5 (long-term): 15.2% mean weight loss at 104 weeks

Zepbound/Mounjaro — SURMOUNT trial programme: - SURMOUNT-1 (non-diabetic obesity, 15mg): 22.5% mean weight loss at 72 weeks - SURMOUNT-2 (type 2 diabetes, 15mg): 14.7% mean weight loss at 72 weeks - SURMOUNT-3 (with prior intensive lifestyle): 26.6% mean weight loss at 84 weeks - SURMOUNT-4 (withdrawal study): Demonstrated significant weight regain after discontinuation

Direct comparison at the highest doses:

| Metric | Wegovy 2.4mg | Zepbound 15mg | |--------|-------------|---------------| | Mean weight loss | ~15% | ~22.5% | | ≥5% weight loss | 86% | 96% | | ≥10% weight loss | 69% | 85% | | ≥15% weight loss | 51% | 78% | | ≥20% weight loss | 32% | 63% |

The SURPASS-2 head-to-head trial: The most important comparison comes from SURPASS-2, which directly compared tirzepatide against semaglutide 1mg (not 2.4mg) in type 2 diabetes: - Tirzepatide 15mg: −12.4 kg weight loss - Semaglutide 1mg: −6.2 kg weight loss - Tirzepatide achieved approximately twice the weight loss of semaglutide

Important caveats: - No trial has directly compared Zepbound 15mg against Wegovy 2.4mg — the comparison relies on cross-trial analysis, which has limitations - Individual responses vary significantly; some patients respond better to semaglutide than tirzepatide - Trial populations, durations, and endpoints differ slightly between programmes - Real-world results may differ from clinical trial results due to adherence, lifestyle factors, and population differences

Both medications share common incretin-related side effects but differ in their tolerability profiles:

Gastrointestinal side effects (the most common for both):

| Side Effect | Wegovy 2.4mg | Zepbound 15mg | |------------|-------------|---------------| | Nausea | ~44% | ~29% | | Diarrhoea | ~30% | ~23% | | Vomiting | ~24% | ~12% | | Constipation | ~24% | ~16% | | Abdominal pain | ~20% | ~14% |

Key tolerability finding: Despite producing more weight loss, Zepbound/tirzepatide generally causes fewer and less severe GI side effects than Wegovy/semaglutide. This is a significant practical advantage — GI intolerance is the primary reason patients discontinue incretin-based therapy.

Why might Zepbound be better tolerated? The GIP receptor component may play a role. Research suggests that GIP activation can counteract some of the nausea-inducing effects of GLP-1 receptor activation. Additionally, tirzepatide's pharmacokinetic profile may result in smoother receptor activation compared to semaglutide.

Discontinuation rates due to adverse events: - Wegovy (STEP trials): approximately 7% - Zepbound (SURMOUNT trials): approximately 5–6%

Serious adverse events (rare but important for both): - Pancreatitis: Rare with both; monitor for severe abdominal pain - Gallbladder events: Increased with rapid weight loss (both medications) - Thyroid C-cell concerns: Theoretical (rodent data); no confirmed human cases - Hypoglycaemia: Low risk when used without insulin or sulfonylureas

Cardiovascular safety: - Wegovy has proven cardiovascular benefit from the SELECT trial (20% MACE reduction) — this is a significant advantage - Zepbound's dedicated cardiovascular outcomes trial (SURPASS-CVOT) is ongoing; results are not yet available - Until CVOT data is available for tirzepatide, Wegovy has a stronger evidence base for cardiovascular risk reduction

The cardiovascular question is critical: For patients with established cardiovascular disease or high cardiovascular risk, Wegovy currently has the stronger evidence base. This is a factor that could influence prescribing decisions, particularly in the NHS setting where cardiovascular benefit adds to the cost-effectiveness argument.

Access to both medications in the UK involves navigating regulatory status, supply, and funding:

Wegovy UK availability: - MHRA approved and available since 2022 - NICE approved for NHS use (TA875) with specific eligibility criteria - Available through private prescriptions - Supply has been intermittent but improving - Private cost: approximately £220–300/month at maintenance dose - NHS: standard prescription charge (free in Scotland, Wales, NI)

Zepbound/tirzepatide UK availability: - Mounjaro (tirzepatide for diabetes) is MHRA approved and available - Zepbound branding for weight management: UK regulatory status evolving - Tirzepatide is being prescribed off-label for weight management by some private clinics - NICE appraisal for weight management indication: in progress - Private cost: approximately £250–320/month at maintenance dose - NHS for weight management: not yet available (available for type 2 diabetes as Mounjaro)

Comparative access summary:

| Factor | Wegovy | Zepbound/Tirzepatide | |--------|--------|---------------------| | MHRA approved for weight loss | Yes | Evolving | | NICE approved for NHS weight loss | Yes | Pending | | Available privately | Yes | Yes (off-label) | | Monthly private cost | £220–300 | £250–320 | | Supply reliability | Improving | Generally good | | Cardiovascular data | SELECT trial | CVOT ongoing |

Choosing a private provider: Whether seeking Wegovy or Zepbound/tirzepatide, the principles for selecting a provider are the same: - Verify GMC registration of the prescriber - Ensure a genuine clinical assessment is conducted - Confirm that the medication is sourced from a licensed UK pharmacy - Look for ongoing monitoring and support, not just a one-off prescription - Be wary of services offering guaranteed prescriptions or unusually low prices

Choosing between Zepbound and Wegovy requires weighing several factors against your individual circumstances:

Zepbound (tirzepatide) may be preferable if: - Maximum weight loss is your primary goal - You are concerned about GI side effects (better tolerated overall) - You have type 2 diabetes (dual mechanism offers additional glycaemic benefits) - You can access it through a private prescriber - You are willing to pay the slightly higher cost - You have previously tried semaglutide with insufficient response

Wegovy (semaglutide) may be preferable if: - You have cardiovascular disease or high cardiovascular risk (SELECT trial data) - You want a medication with established NICE approval for NHS funding - Cost is a significant factor (slightly more affordable privately) - You want the most established evidence base (longer track record) - Supply reliability is important to you - You prefer a medication specifically licensed in the UK for weight management

Factors that apply to both: - Neither is a standalone solution — lifestyle changes remain essential - Weight regain occurs after discontinuation unless habits have changed - Both require medical supervision and ongoing monitoring - Individual response varies — what works best can only be determined by trying - Both are serious medications with real side effects and contraindications

Practical decision pathway:

1. Assess your health profile: Do you have cardiovascular disease? Type 2 diabetes? Other comorbidities? This may guide the choice. 2. Explore NHS options: If you meet eligibility criteria, NHS access to Wegovy eliminates cost as a factor. 3. If going private, compare providers: Look at total cost (medication + consultations + monitoring), not just the medication price. 4. Discuss with your prescriber: A qualified clinician who knows your medical history is the best person to recommend between the two. 5. Be prepared to switch: If your first choice does not work well after adequate dose escalation, switching to the alternative is a reasonable next step.

The bottom line: Both Zepbound and Wegovy are highly effective, evidence-based weight loss medications. The "best" choice depends on your individual health profile, access, budget, and treatment goals. Either option, combined with lifestyle modifications, can produce life-changing results.

*This guide is for educational purposes only. Always consult a qualified healthcare professional for personalised medical advice.*